Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
Rhea-AI Summary
Biofrontera Inc. (Nasdaq: BFRI) announced it will report its financial results for Q4 and the full year ended December 31, 2021, on April 8, 2022, prior to the opening of U.S. markets. The company will host a conference call at 11:00 a.m. ET the same day to discuss these results and provide a business update.
The call can be accessed through a toll-free number for U.S. participants and an international line. A webcast of the call will also be available for live viewing and a 90-day replay.
Positive
- Scheduled release of Q4 and full-year financial results could provide clarity on business performance.
- Conference call allows for direct communication with investors, potentially increasing investor confidence.
Negative
- None.
News Market Reaction – BFRI
In the trading session that priced this news, BFRI gained 5.41%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call |
| Date: | Friday, April 8, 2022 |
| Time: | 11:00 a.m. Eastern time |
| Conference call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: | Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com. |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit https://www.biofrontera-us.com.
Contacts
Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com
